Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
1. EBS received a $30 million BARDA contract modification for CYFENDUS®. 2. Deliveries of the anthrax vaccine will begin this year and complete by March 2026. 3. CYFENDUS® is critical for U.S. national security against bio-threats like anthrax. 4. Previous contract for CYFENDUS® modification was $50 million in December 2024. 5. CYFENDUS® approved by FDA for post-exposure anthrax prophylaxis in July 2023.